Healthcare
MALDI mass spectrometry imaging: 3 growing applications
Alcimed presents 3 innovative fields of application of this fast growing MALDI technology.
Logbook
Filter:
Cross-sector
New vegetable fiber-based materials: 4 levers to massify their use
What are the 4 main levers to massify the use of vegetable fiber materials in industries?
Healthcare
HERA in EU: the new agency to anticipate the next health emergencies
Alcimed revisits the creation of the HERA EU agency and its future challenges compared with its US twin, BARDA.
Energy - Environment - Mobility
Autonomous robotics: heading towards robots closer and closer to humans for industrial applications?
Autonomous industrial robotics: robots to assist humans Since the first robotic solutions developed at the beginning of the 20th century, such as John Hammond and Benjamin Miessner's electric dog in ...
Articles
Long Acting injectable antiretrovirals: more than just a change in formulation
What are the advantages of this injectable dual antiretroviral therapy? What challenges will need to be overcome to enable its development?
Cosmetics
In-Cosmetics 2022: how to develop sustainable cosmetic products?
Sustainable cosmetics: labels to meet societal expectations According to a study conducted by Euromonitor International* and presented during the show, consumers' expectations in terms of cosmetics ...
Energy - Environment - Mobility
What if reaching carbon neutrality allowed France to become energy independent?
What if decarbonizing our energy production was a lever for achieving greater energy independence for France?
Cross-sector
Zoonoses prevention and food security: towards a proactive approach
What is the impact of zoonoses on food security? What digital innovations in development can improve early detection?
Healthcare
Human digital twins for personalized medicine: a new promising technology?
Overview of the concept, usages, and limits of the Digital Twin technology and the new concept of Human Digital Twins.
Healthcare
Intratumoral immunotherapy: utilizing the tumor to kill itself
What are the advantages and hurdles of intratumoral immunotherapy? What can we learn from the increasing number of tests in clinical phases?